Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments: 2016-2024

Historic Change in Acquisitions & Divestments for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Dec 2024 value amounting to $260.6 million.

  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments rose 35.75% to $61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.4 million, marking a year-over-year increase of 21.98%. This contributed to the annual value of $260.6 million for FY2024, which is 26.57% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $260.6 million for FY2024, which was down 26.57% from $355.0 million recorded in FY2023.
  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $361.2 million during FY2021, with a 5-year trough of $245.6 million in FY2020.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $284.2 million (2022), whereas its average is $300.0 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 47.08% in 2021, then fell by 26.57% in 2024.
  • Over the past 5 years, Rhythm Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $245.6 million in 2020, then spiked by 47.08% to $361.2 million in 2021, then dropped by 21.32% to $284.2 million in 2022, then rose by 24.88% to $355.0 million in 2023, then declined by 26.57% to $260.6 million in 2024.